Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT03059355
Other study ID # 20170095
Secondary ID
Status Terminated
Phase Phase 1/Phase 2
First received
Last updated
Start date April 12, 2018
Est. completion date February 11, 2021

Study information

Verified date October 2022
Source University of Miami
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is to compare the safety and efficacy of UCMSCs and BMMSCs administered intravenously in patients to evaluate cytokine suppression in patients with chronic inflammation. Cells administered via intravenous infusion (IV) and will be tested in 37 patients in two phases (Pilot and Randomized).


Recruitment information / eligibility

Status Terminated
Enrollment 14
Est. completion date February 11, 2021
Est. primary completion date March 23, 2020
Accepts healthy volunteers No
Gender All
Age group 21 Years to 95 Years
Eligibility Inclusion Criteria: - Provide written informed consent - Subjects age > 21 and < 95 years at the time of signing the Informed Consent Form. - Each subject must have endothelial dysfunction. Endothelial dysfunction Criteria: Impaired flow-mediated vasodilation (FMD <7%) • At the time of enrollment, each subject must meet at least 3 out of the 5 criteria under the harmonized definition of the metabolic syndrome, consisting of the following: - Waist circumference - US defined: = 102 cm (males) or = 88 cm (females) - Elevated triglycerides - = 150 mg/dL (1.7 mM) - Reduced HDL-C - Males: <40 mg/dL (1.0 mM) Females: <50 mg/dL (1.3 mM) - Elevated blood pressure - Systolic = 130 mm Hg and/or Diastolic = 85 mm Hg - Elevated fasting glucose - = 100 mg/dL Exclusion Criteria: - Be a female who is pregnant, nursing, or of childbearing potential while not practicing effective contraceptive methods. Female subjects must undergo a blood or urine pregnancy test at screening and within 36 hours prior to infusion. - Inability to perform any of the assessments required for endpoint analysis. - Active listing (or expected future listing) for transplant of any organ. - Clinically important abnormal screening laboratory values, as determined by the P.I. - Serious comorbid illness or any other condition that, in the opinion of the investigator, may compromise the safety or compliance of the subject or preclude successful completion of the study. - Have known allergies to penicillin or streptomycin. - Hypersensitivity to dimethyl sulfoxide (DMSO). - Be a solid organ transplant recipient. This does not include prior cell-based therapy (>12 months prior enrollment) bone, skin, ligament, tendon or corneal grafting. Have a history of organ or cell transplant rejection. - Have a clinical history of malignancy within 3 years (i.e., subjects with prior malignancy must be disease free for 3 years), except curatively- treated basal cell carcinoma, squamous cell carcinoma, melanoma in situ or cervical carcinoma, if recurrence occurs. - Have a non-pulmonary condition that limits lifespan to < 1 year. - History of drug abuse (illegal "street" drugs except marijuana, or prescription medications not being used appropriately for a pre-existing medical condition) or alcohol abuse (= 5 drinks/day for ? 3 months), or documented medical, occupational, or legal problems arising from the use of alcohol or drugs within the past 24 months. - Be serum positive for HIV, hepatitis B surface antigen or Viremic hepatitis C, and/or Syphilis. - Be currently participating (or participated within the previous 30 days) in an investigational therapeutic or device trial. - Patients with Ejection Fraction <45% (heart failure patients). - Glomerular Filtration Rate < or equal to 35 (chronic kidney disease stage 3 or higher). - Liver disease (elevated Liver Function Tests greater than 3x normal limit). - Advanced pulmonary disease (requiring home oxygen and/or less than 1 expected life span). - Proliferative diabetic retinopathy - Hemoglobin A1C greater than 7.

Study Design


Intervention

Biological:
UCMSCs
Allogeneic Umbilical Cord Tissue derived MSCs (UCMSCs)
BMMSCs
Bone Marrow derived Mesenchymal Stem Cells (BMMSCs)
Other:
Placebo
a single administration of placebo delivered via peripheral intravenous infusion.

Locations

Country Name City State
United States ISCI / University of Miami Miller School of Medicine Miami Florida

Sponsors (2)

Lead Sponsor Collaborator
Joshua M Hare The Marcus Foundation

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Treatment-Emergent Serious Adverse Events (TE-SAEs) Number of treatment-emergent serious adverse events (SAE) (at one-month post infusion), defined as the composite of: death, non-fatal pulmonary embolism, stroke, hospitalization for worsening dyspnea and clinically significant laboratory test abnormalities, determined per the Investigator's judgment. one month post infusion
Secondary Cytokine Levels Cytokine levels including the following panel of inflammatory and angiogenic markers: Interleukin-1 (IL-1), Interleukin-6 (IL-6), Tumor Necrosis Factor alpha (TNFa), and Vascular Endothelial Growth Factor (VEGF), & Stromal Cell Derived Factor (SDF-1a) levels from serum/plasma samples all measured in pg/mL. at Baseline, at Week 2, at Month 1, at Month 3, and at Month 6
Secondary hsCRP Levels values at baseline and follow up for the following inflammatory marker: Serum High sensitivity C-Reactive Protein (hsCRP) in mg/L. at Baseline, at Week 2, at Month 1, at Month 3, and at Month 6
Secondary Stem Cell Factor (SCF) Levels SCF levels from serum/plasma samples measured in units of mg/mL at Baseline, at Week 2, at Month 1, at Month 3, and at Month 6
Secondary Endothelial Progenitor Cell-Colony Forming Units (EPC-CFUs) Endothelial function will be reported as the change in Endothelial Progenitor Cell Colony Forming Unit (EPC-CFU) assessed via blood sample assay at Baseline, and at 3 months
Secondary Flow Mediated Diameter Percentage (FMD%) FMD% will be assessed using brachial artery ultrasound at Baseline and at Month 3
See also
  Status Clinical Trial Phase
Recruiting NCT04635202 - Effect of Elliptical Training on Metabolic Homeostasis in Metabolic Syndrome N/A
Completed NCT04053686 - An Intervention to Reduce Prolonged Sitting in Police Staff N/A
Completed NCT05343858 - Pilot Study to Evaluate the Effect of Two Microalgae Consumption on Metabolic Syndrome N/A
Active, not recruiting NCT05891834 - Study of INV-202 in Patients With Obesity and Metabolic Syndrome Phase 2
Recruiting NCT05040958 - Carotid Atherosclerotic Plaque Load and Neck Circumference
Completed NCT03644524 - Heat Therapy and Cardiometabolic Health in Obese Women N/A
Active, not recruiting NCT02500147 - Metformin for Ectopic Fat Deposition and Metabolic Markers in Polycystic Ovary Syndrome (PCOS) Phase 4
Recruiting NCT03227575 - Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control N/A
Recruiting NCT05972564 - The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function Phase 1/Phase 2
Completed NCT03289897 - Non-invasive Rapid Assessment of NAFLD Using Magnetic Resonance Imaging With LiverMultiScan N/A
Recruiting NCT05956886 - Sleep Chatbot Intervention for Emerging Black/African American Adults N/A
Completed NCT06057896 - Effects of Combined Natural Molecules on Metabolic Syndrome in Menopausal Women
Active, not recruiting NCT03613740 - Effect of Fucoxanthin on the Metabolic Syndrome, Insulin Sensitivity and Insulin Secretion Phase 2
Completed NCT04498455 - Study of a Prebiotic Supplement to Mitigate Excessive Weight Gain Among Physicians in Residency Phase 4
Completed NCT05688917 - Green Coffee Effect on Metabolic Syndrome N/A
Completed NCT04117802 - Effects of Maple Syrup on Gut Microbiota Diversity and Metabolic Syndrome N/A
Completed NCT03697382 - Effect of Daily Steps on Fat Metabolism N/A
Completed NCT03241121 - Study of Eating Patterns With a Smartphone App and the Effects of Time Restricted Feeding in the Metabolic Syndrome N/A
Completed NCT04509206 - Virtual Teaching Kitchen N/A
Completed NCT05124847 - TREating Pediatric Obesity N/A